Mercaptopurine
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: 6-mercaptopurine, 6-mercaptopurine monohydrate, mercaptopurine hydrate, mercaptopurine monohydrate, mercapurin, purimethol, purinethiol, purinethol, thiohypoxanthine, xaluprine
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Mercaptopurine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1953. DrugCentral lists 7 molecular targets, including PTGS1, punA and ABCC4. Recorded indications include Acute lymphoid leukemia and Acute promyelocytic leukemia, FAB M3.
- Approval status: ofp (first approved 1953 by the FDA).
- Molecular targets: PTGS1, punA, ABCC4 and PPAT (7 listed in DrugCentral).
- Indications: Acute lymphoid leukemia and Acute promyelocytic leukemia, FAB M3.
- ATC code: L01BB02 (Purine analogues).
- Molecular formula: C5H4N4S; molecular weight 152.18 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Acute lymphoid leukemia
- Acute promyelocytic leukemia, FAB M3
Off-label uses (5)
- Acute myeloid leukemia, disease
- Crohn's disease
- Polycythemia vera
- Psoriasis with arthropathy
- Ulcerative colitis
Contraindications (19)
- Acute pancreatitis
- Anemia
- Ascites
- Bone marrow depression
- Breastfeeding (mother)
- Chemotherapy-Induced Hyperuricemia
- Dehydration
- Disease of liver
- Gastrointestinal ulcer
- Hepatosplenic T-cell lymphoma
- Hyperbilirubinemia
- Kidney disease
- Leukopenia
- Liver function tests abnormal
- Neutropenic disorder
- Obstruction of bile duct
- Pregnancy, function
- Thiopurine S-Methyltransferase Deficiency
- Thrombocytopenic disorder
Mechanism & targets
Molecular targets (7)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | PTGS1 | unknown | IC50 4.79 |
| Purine nucleoside phosphorylase | punA | unknown | Kd 4.10 |
| Multidrug resistance-associated protein 4 | ABCC4 | unknown | — |
| Amidophosphoribosyltransferase | PPAT | inhibitor | — |
| Thiopurine S-methyltransferase | TPMT | unknown | — |
| Purine nucleoside phosphorylase | PNP | unknown | — |
| Multidrug resistance-associated protein 5 | ABCC5 | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1953-09-11 | FDA | — | STASON PHARMS |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L01BB02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ANTIMETABOLITES › Purine analogues |
Pharmacogenomics
Drug-label and guideline annotations from PharmGKB and CPIC.
- EMA label: NUDT15, TPMT · Testing Recommended
- FDA label: NUDT15, TPMT · Testing Recommended
- HCSC label: NUDT15, TPMT · Testing Recommended
- Swissmedic label: NUDT15, TPMT · Actionable PGx
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Febrile neutropenia | 2856.4 |
| Febrile bone marrow aplasia | 807.5 |
| Secondary immunodeficiency | 538.4 |
| Venoocclusive liver disease | 520.2 |
| Bacterial infection | 450.7 |
| Mycobacterium chelonae infection | 443.3 |
| Hypertriglyceridaemia | 417.0 |
| Human bocavirus infection | 413.5 |
| Rhinovirus infection | 406.5 |
| Acute lymphocytic leukaemia recurrent | 405.4 |
| Myelosuppression | 375.1 |
| Pancytopenia | 364.3 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Mercaptopurine is on its molecule page.
| Molecular formula | C5H4N4S |
|---|---|
| Molecular weight | 152.18 g/mol |
| CAS number | 50-44-2 |
| InChIKey | GLVAUDGFNGKCSF-UHFFFAOYSA-N |
| PubChem CID | 667490 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Mercaptopurine used for?
DrugCentral lists the following indications for Mercaptopurine: Acute lymphoid leukemia and Acute promyelocytic leukemia, FAB M3.
How does Mercaptopurine work?
Its molecular targets in DrugCentral include PTGS1, punA, ABCC4 and PPAT (inhibitor).
When was Mercaptopurine first approved?
Mercaptopurine was first approved by the FDA in 1953.
What is the chemical formula of Mercaptopurine?
Mercaptopurine has the molecular formula C5H4N4S and a molecular weight of 152.18 g/mol.
Browse: all drugs starting with M · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1708 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1200751 — compound record and bioactivity
- PubChem CID 667490 — chemical identifiers
- DrugBank DB01033 — drug record
- FDA UNII E7WED276I5 — substance identity
- DailyMed: FDA labels for Mercaptopurine — current prescribing information (label search)
- UniProt P23219 (PTGS1) — target protein
- UniProt O15439 (ABCC4) — target protein
- UniProt Q06203 (PPAT) — target protein
- UniProt P51580 (TPMT) — target protein
- UniProt P00491 (PNP) — target protein
- UniProt O15440 (ABCC5) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
- PharmGKB / CPIC — pharmacogenomic label annotations
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.